2016, Number 5
<< Back Next >>
Med Int Mex 2016; 32 (5)
Comparison of serum lead levels in patients with chronic renal failure in treatment with hemodialysis, peritoneal dialysis and conservative treatment
Rodríguez-Chagolla JM, Ruíz-Mejía R, García-Alcalá MC, Valdespino- Vázquez MY, García-Nava M, Mateos-Toledo H
Language: Spanish
References: 22
Page: 507-514
PDF size: 622.50 Kb.
ABSTRACT
Background: There is a growing burden of diseases such as hypertension
and diabetes mellitus. It is estimated that 25-40% of these
patients will develop kidney failure and require renal replacement
therapy. Alterations are known in the metabolism of elements such
as lead in patients with renal failure, as well as the presence of high
concentrations of lead in these patients.
Objetive: To compare serum levels of lead in patients with different
types of renal replacement therapy.
Material and Method: A cross-sectional study was done, where
the serum levels of lead were compared in 57 patients with chronic
renal disease without replacement therapy (WRT), 21 subjects on
hemodialysis (HD) and 24 treated with peritoneal dialysis (PD). They
were divided into 3 groups according to serum levels of lead: group
1: ‹5 µg/dL, group 2: 5.1-9.9 µg/dL and group 3: ›10 µg/dL.
Results: The average serum levels of lead were of 5.9 μg/dL for group
without replacement therapy, 5.9 µg/dL in peritoneal dialysis group
and 4.7 µg/dL in hemodialysis group (p=0.209). A greater number of
cases with serum levels of lead ›10µg/dL was found in group without
replacement therapy (p=0.060). The hemodialysis and peritoneal
dialysis groups showed no differences from the serum levels of lead.
Conclusions: In general, there were serum levels of lead similar
to those found in the national literature, there were no differences in
serum levels of lead among groups.
REFERENCES
Fewtrell L, Kaufmann R, Prüss-Üstün A. Lead: assessing the environmental burden of disease at national and local levels. Geneva: World Health Organization 2003. (WHO Environmental Burden of Disease Series, No. 2).
World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization, 2009.
Caravanos J, Dowling R, Téllez-Rojo MM y col. Niveles de plomo en sangre en México. Icahn School of Medicine at Mount Sinai. Ann Global Health 2014;80:1-11.
Staessen JA, Lauwerys RR, Buchet JP, et al. Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group. N Engl J Med 1992;327:151-156.
Kim R, Rotnitzky A, Sparrow D, Weiss ST, et al. A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA 1996;275:1177-1781.
Lin JL, Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progressive renal insufficiency. Arch Intern Med. 2001;161:264-271.
Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. New Engl J Med 2003;348:277-286.
Lin-Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant 2007;22:2924-2931.
Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006;114:1388-1394.
Huang WH, Lin JL, Lin-Tan DT, et al. Environmental lead exposure accelerates progressive diabetic nephropathy in type II diabetic patients. Biomed Res Int 2013;2013: 742545.
Soderland P, Loverkar S, Weiner DE, et al. Chronic kidney disease which is associated with environmental toxins and exposures. Adv Chronic Kidney Dis 2010;17:254-264.
Lin JL, et al. Lead and mortality in patients on MHD. Am J Med 2011;124:350-358.
M SP, Rajan PM, Santhi S, Jothimalar. Blood lead in endstage renal disease (ESRD) patients who were on maintenance haemodialysis. J Clin Diagn Res 2012;6:1633-1635.
Krachler M, Wirnsberger GH. Long-term changes of plasma trace element concentrations in chronic hemodialysis patients. Blood Purif 2000;18:138-143.
Colleoni N, Arrigo G, Gandini E, Corigliano C, D’Amico G. Blood lead in hemodialysis patients. Am J Nephrol 1993;13:198-202.
Kessler M, Durand PY, Huu TC, et al. Mobilization of lead from bone in end-stage renal failure patients with secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2731-2733.
Lin JL, Lin-Tan DT, Yen TH, et al. Blood lead levels, malnutrition, inflammation, and mortality in patients with diabetes treated by long-term hemodialysis. Am J Kidney Dis 2008;51:107-115.
Lin JL, Lin-Tan DT, Chen KH, et al. Blood lead levels association with 18-month all-cause mortality in patients with chronic peritoneal dialysis. Nephrol Dial Transplant 2010;25:1627-1633.
Lin JL, Lin-Tan DT, Yen TH, Hsu CW, et al. Blood lead levels, malnutrition, inflammation, and mortality in patients with diabetes treated by long-term hemodialysis. Am J Kidney Dis 2008;51(1):107-115.
Tonelli M, Wiebe N, Hemmelgarn B, et al. Trace elements in hemodialysis patients: a systematic review and meta-analysis. BMC Medicine 2009;7:25 doi:10.1186/1741-7015-7-25.
Weaver VM, Fadrowski JJ, Jaar BG. Global dimensions of chronic kidney disease of unknown etiology (CKDu): a modern era environmental and/or occupational nephropathy? BMC Nephrology 2015;16:145.
Gerhardsson L, Lundström NG, Nordberg G, Wall S. Mortality and lead exposure: a retrospective cohort study of Swedish smelter workers. Br J Ind Med 1986;43:707-712.
Full text